Skip to content

Interim report January-June 2022: ACCELERATING GROWTH AND PROFITABILITY

SECOND QUARTER 2022 (APR – JUN)

Net sales amounted to SEK 188.2 million (36.6), corresponding to an increase of 415 percent compared with the corresponding period in the preceding year.

For comparable units, sales increased by 46 percent.

Operating profit amounted to SEK 38.6 million (2.2).

Net profit amounted to SEK 26.5 million (3.5), corresponding to earnings per share of SEK 0.52 (0.09).

Cash flow from operating activities amounted to an inflow of SEK 30.4 million (9.4). As of June 30, 2022, cash and cash equivalents amounted to SEK 362.3 million (267.3).

At the end of May, Surgical Science announced that its US operations had secured an order valued at USD 6.7 million (equivalent to about SEK 65.9 million) from a major US hospital chain. About USD 2.1 million of this order was recognized as revenue in the second quarter.

FIRST HALF OF 2022 (JAN–JUN)

Net sales amounted to SEK 347.4 million (73.8), corresponding to an increase of 371 percent compared with the corresponding period in the preceding year.

For comparable units, sales increased by 40 percent.

Operating profit amounted to SEK 58.6 million (4.5).

Net profit amounted to SEK 43.0 million (5.0), corresponding to earnings per share of SEK 0.85 (0.13).

Cash flow from operating activities amounted to an inflow of SEK 41.5 million (0.5).

Gothenburg, Sweden, August 25, 2022
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

Skip to navigation